Stellar International's URACYST®–S Receives European Regulatory Approval

Stellar International's URACYST®–S Receives European Regulatory Approval London, Ontario October 2, 2003 – Stellar International Inc. (TSXV: YYS OTCBB:SLRXF ), a Canadian pharmaceutical developer and marketer of high quality, cost-effective products for select health care markets, today reported that G. Pohl-Boskamp GmbH & Co., Stellar’s European licensee for Uracyst®-S, has received European regulatory approval for the product. “This is the news we have been waiting for,” stated Peter Riehl, Stellar’s President and Chief Executive Officer. “It allows Pohl-Boskamp to prepare for the near-term European launch of Uracyst®-S / Uropol-S. Uracyst®-S will provide a significant addition to the armamentarium European physicians have for the treatment of GAG deficient cystitis, a chronic debilitating and difficult to manage bladder syndrome.” Pohl-Boskamp is an integrated pharmaceutical company with a well established presence in the Pan-European market where it focuses on their proprietary medicines and niche pharmaceutical markets. Given Pohl-Boskamp’s experience in niche marketing, Uracyst®-S has the potential of becoming a very successful product in the European market. Stellar International has developed and is marketing three products in Canada based on its core polysaccharide technology: NeoVisc®, for the treatment of osteoarthritis, Uracyst®-S and the Uracyst Test Kit, Stellar’s patented technology for the diagnosis and treatment of Interstitial Cystitis (IC), an inflammatory disease of the urinary bladder wall. The Uracyst® treatment for IC costs less than competing products and has shown a good symptomatic response rate. Stellar also has an in-licensing agreement for Skelite™ a proprietary synthetic bone-grafting product which is expected to positively impact sales in 2003. The TSX Venture Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of this release. This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995. Readers are cautioned not to place undue reliance on these forward-looking statements. Actual results may differ materially from those indicated by these forward-looking statements as a result of risks and uncertainties impacting the Company's business including increased competition; the ability of the Company to expand its operations, to attract and retain qualified professionals, technological obsolescence; general economic conditions; and other risks detailed time to time in the Company's filings. For more information contact: Peter Riehl, President & CEO (800) 639-0643 (519) 434 -1540 Herbert Lanzet/DeeDee Lanzet H.L. Lanzet, Inc (212) 888-4570